Uncategorized
This week in Drug Discovery (16 – 20 March)

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.
This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.
The top stories:
Edinburgh team makes Parkinson’s drug from plastic bottles
A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows.
Read more…
Cancer enzyme discovery opens new avenues for drug discovery
Researchers have identified the enzyme DHX8 as a crucial regulator of the stress response protein HSF1, which may have potential to open new avenues for future drug development.
Research identifies new target for multiple myeloma treatment
New research published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma.
First patient dosed in ROR1-positive blood cancer treatment
The first patient has been dosed with NVG-222, a treatment for ROR1-positive blood cancers developed by biotechnology company NovalGen.
Rare disease drugs to generate $400bn by 2032, report reveals
Evaluate’s ‘2026 Orphan Drug Report’ predicts the sales of orphan drugs will continue to rise steadily, despite policy changes and pricing turmoil. According to the forecast, orphan drugs will account for over 21% of all prescription pharmaceutical drugs by 2032.
Read more…
The post This week in Drug Discovery (16 – 20 March) appeared first on Drug Discovery World (DDW).
Uncategorized
An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Uncategorized
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.
But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.
WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.
But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.
Uncategorized
Nonprofit buys experimental cancer drug to maintain patient access
In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.
As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, will also acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last.
In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.
As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, will also acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform